Conclusions

• Analysis of the 1-year follow up data shows that treatment with T/O results in a lower risk of escalation to triple therapy, COPD exacerbations, pneumonia and an adverse outcome versus LABA/ICS in COPD patients
• The reduction in the risk of an adverse outcome was similar irrespective of baseline eosinophils and exacerbation history

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; T/O, tiotropium/olodaterol.